Ex­clu­sive: Top neu­ro­sci­en­tist Asa Abe­liovich tar­gets ALS, schiz­o­phre­nia with new start­up Leal af­ter $1B Lil­ly buy­out

Af­ter strik­ing a bil­lion-dol­lar deal for his last start­up, Asa Abe­liovich has built a new ven­ture with even grander am­bi­tions in treat­ing some of the biggest neu­ro­log­i­cal dis­eases.

Abe­liovich ex­clu­sive­ly told End­points News about Leal Ther­a­peu­tics, his newest biotech that has op­er­at­ed in stealth for over two years. The Worces­ter, MA-head­quar­tered start­up raised a $39 mil­lion seed round in 2022, and is now rais­ing its next fi­nanc­ing to go in­to the clin­ic with its two lead drugs: LTX-001 in schiz­o­phre­nia and LTX-002 in ALS. The com­pa­ny plans to file IND ap­pli­ca­tions for both pro­grams in the sec­ond half of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER